Skip to main content

Table 1 Demographic and clinical characteristics of the eligible patients with a completed EQ-5D-5L

From: Impacts of the preceding cancer-specific health-related quality of life instruments on the responses to the subsequent EQ-5D-5L

Characteristic

Group 1 (N = 300)

Group 2 (N = 306)

Group 3 (N = 331)

Age (in years)

68 (58–75)

67 (58–73)

68 (59–74)

Sex

   

 Male

157 (52%)

163 (53%)

189 (57%)

 Female

143 (48%)

143 (47%)

142 (43%)

Tumor type

   

 Lung cancer

108 (36%)

108 (35%)

113 (34%)

 Stomach cancer

21 (7%)

22 (7%)

23 (7%)

 Colorectal cancer

79 (26%)

73 (24%)

80 (24%)

 Breast cancer

37 (12%)

35 (11%)

44 (13%)

 Other solid tumors

55 (18%)

68 (22%)

71 (21%)

Stage at diagnosis

   

 I

12 (4%)

19 (6%)

18 (5%)

 II

23 (8%)

17 (6%)

34 (10%)

 III

63 (21%)

64 (21%)

65 (20%)

 IV

200 (67%)

204 (67%)

206 (62%)

 Unknown

2 (1%)

2 (1%)

8 (2%)

Site of metastasis or recurrencea

   

 None

26 (9%)

22 (7%)

35 (11%)

 Liver

60 (20%)

72 (24%)

79 (24%)

 Lung

110 (37%)

95 (31%)

91 (27%)

 Bone

48 (16%)

54 (18%)

67 (20%)

 Brain

34 (11%)

35 (11%)

31 (9%)

 Lymph nodes

124 (41%)

129 (42%)

120 (36%)

 Others

69 (23%)

73 (24%)

90 (27%)

History of surgery

   

 Yes

159 (53%)

152 (50%)

186 (56%)

 No

141 (47%)

154 (50%)

144 (44%)

 Unknown

0 (0%)

0 (0%)

1 (0%)

Hospitalization

   

 Yes

60 (20%)

71 (23%)

64 (19%)

 No

240 (80%)

235 (77%)

267 (81%)

ECOG performance status

   

 0

156 (52%)

148 (48%)

160 (48%)

 1

115 (38%)

127 (42%)

143 (43%)

 2

21 (7%)

21 (7%)

25 (8%)

 3

7 (2%)

10 (3%)

3 (1%)

 Unknown (0, 1, 2, or 3)

1 (0%)

0 (0%)

0 (0%)

Type of treatmenta

   

 Chemotherapy

186 (62%)

195 (64%)

225 (68%)

 Endocrine therapy

20 (7%)

22 (7%)

25 (8%)

 Molecular targeted therapy

56 (19%)

49 (16%)

58 (18%)

 Immunotherapy

38 (13%)

43 (14%)

31 (9%)

 Palliative therapy

17 (6%)

10 (3%)

10 (3%)

 Others

3 (1%)

2 (1%)

3 (1%)

Adverse event at enrollment

   

 Yes

186 (62%)

200 (65%)

220 (66%)

 No

113 (38%)

106 (35%)

110 (33%)

 Unknown

1 (0%)

0 (0%)

1 (0%)

  1. The median (IQR) and the number (%) were reported for age and other characteristics, respectively. Groups 1, 2, and 3 consisted of the two questionnaire types that had the EQ-5D-5L in the first, second, and last places, respectively
  2. ECOG, Eastern Cooperative Oncology Group; IQR, interquartile range
  3. aMultiple choices were allowed